drugset / Trial / NCT00477373

Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study

NCT00477373

Phase 4 Completed 70 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the efficacy of Di-valproate in Bipolar I patients suffering from a manic episode according to DSM IV (APA 1994) over a 12 weeks period of treatment. To evaluate the clinical safety of Di-valproate.

Timeline

Start
2006-12
Primary completion
2007-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproate Unknown 500 mg

Indications